Equities research analysts forecast that Oxford Immunotec Global PLC (NASDAQ:OXFD) will post $30.11 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Oxford Immunotec Global PLC’s earnings, with estimates ranging from $30.00 million to $30.29 million. Oxford Immunotec Global PLC reported sales of $26.11 million during the same quarter last year, which indicates a positive year-over-year growth rate of 15.3%. The business is scheduled to issue its next earnings results on Tuesday, November 7th.

According to Zacks, analysts expect that Oxford Immunotec Global PLC will report full year sales of $30.11 million for the current year, with estimates ranging from $104.47 million to $105.20 million. For the next year, analysts forecast that the company will post sales of $122.44 million per share, with estimates ranging from $120.43 million to $123.50 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Oxford Immunotec Global PLC.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). The firm had revenue of $26.10 million during the quarter, compared to analyst estimates of $25.05 million. Oxford Immunotec Global PLC had a negative net margin of 34.58% and a negative return on equity of 35.76%. The company’s quarterly revenue was up 35.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.29) earnings per share.

OXFD has been the subject of several analyst reports. ValuEngine upgraded shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research cut shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, August 30th. Cowen and Company restated a “buy” rating and issued a $22.00 target price on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $26.00 target price on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $20.25.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $30.11 Million” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/17/zacks-analysts-anticipate-oxford-immunotec-global-plc-oxfd-will-announce-quarterly-sales-of-30-11-million.html.

Shares of Oxford Immunotec Global PLC (OXFD) opened at 15.32 on Friday. Oxford Immunotec Global PLC has a 12-month low of $11.71 and a 12-month high of $19.51. The stock’s 50 day moving average is $16.14 and its 200 day moving average is $15.48. The firm’s market cap is $353.52 million.

In related news, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $15.82, for a total transaction of $47,460.00. Following the completion of the transaction, the director now directly owns 18,000 shares in the company, valued at approximately $284,760. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Peter Wrighton-Smith sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $16.06, for a total transaction of $481,800.00. Following the transaction, the chief executive officer now owns 491,668 shares of the company’s stock, valued at $7,896,188.08. The disclosure for this sale can be found here. Insiders sold a total of 125,110 shares of company stock valued at $2,059,827 over the last 90 days. Corporate insiders own 7.58% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in OXFD. Teachers Advisors LLC increased its position in Oxford Immunotec Global PLC by 19.6% during the 4th quarter. Teachers Advisors LLC now owns 39,932 shares of the company’s stock worth $597,000 after purchasing an additional 6,550 shares in the last quarter. Nationwide Fund Advisors increased its position in Oxford Immunotec Global PLC by 1.9% during the 1st quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock worth $213,000 after purchasing an additional 254 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Oxford Immunotec Global PLC during the 1st quarter worth approximately $1,135,000. Wells Fargo & Company MN increased its position in Oxford Immunotec Global PLC by 129.2% during the 1st quarter. Wells Fargo & Company MN now owns 65,937 shares of the company’s stock worth $1,021,000 after purchasing an additional 37,163 shares in the last quarter. Finally, Parkwood LLC acquired a new position in Oxford Immunotec Global PLC during the 1st quarter worth approximately $176,000. Institutional investors and hedge funds own 79.13% of the company’s stock.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.